ArticleFrontiers in oncology2025
Case Report and review of the literature: esophageal pleomorphic rhabdomyosarcoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Esophageal pleomorphic rhabdomyosarcoma: a rare high-grade sarcoma managed with upfront resection.Journal of surgical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal rhabdomyosarcoma is an exceedingly rare malignant tumor, with only three cases comprehensively documented in the literature since 1995. Due to its rarity, there is limited information on the epidemiology and diagnosis of this disease, and no standardized treatment protocols have been established. As a result, both the recognition and management of esophageal rhabdomyosarcoma pose significant challenges. The present case report provides valuable insight into the clinical approach to this rare tumor, highlighting the need for further research and investigation to develop more effective diagnostic tools and therapeutic strategies. Case Presentation: We described the case of a 77-year-old male who presented with dyspepsia and anemia, leading to the discovery of an esophageal lesion. At the index endoscopy, histological findings were consistent with esophageal adenocarcinoma. Consequently, the patient was treated with neoadjuvant chemotherapy and Ivor Lewis esophagectomy. Interestingly, on pathological examination the lesion was identified as a pleomorphic rhabdomyosarcoma of the esophagus. Postoperatively, the patient received adjuvant chemotherapy. Subsequently, a subcutaneous metastatic lesion on his right shoulder was treated with a combination of radiotherapy and surgical excision. The patients died twenty-six months after the initial diagnosis. Conclusions: Our case represents one of the few reported instances of esophageal rhabdomyosarcoma, a highly rare and aggressive malignancy, and provides valuable insights into the challenges of diagnosing and managing this disease. Moreover, this is one of the first cases of esophageal rhabdomyosarcoma followed up for more than 24 months. However, given the paucity of data on esophageal rhabdomyosarcoma, there remains a significant unmet need for more comprehensive studies to establish standardized diagnostic and therapeutic protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.